In recent years, the emergence of drugs that target Programmed cell death protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1), the treatment of kidney cancer has marked a shift from the era of targeted therapy to the era of immunotherapy. This evidence concerns the gene CD274 and kidney cancer.